Metabolic · FDA Approved
Albiglutide (Tanzeum)
FDA-approved
01 · Overview
Albiglutide is a GLP-1 receptor agonist made of modified human GLP-1 sequences fused to human albumin, giving it an elimination half-life of about 5 days that allows once-weekly subcutaneous dosing (PMID 28050889). By activating GLP-1 receptors, albiglutide enhances glucose-dependent insulin secretion and suppresses inappropriate glucagon release in patients with type 2 diabetes.
The FDA approved it in 2014 as Tanzeum, but the product has been discontinued and is no longer marketed.
02 · Research summary & key findings
In the HARMONY trial program, albiglutide lowered HbA1c by 0.8 to 1.0 percent versus placebo but produced weight changes similar to placebo, and gastrointestinal side effects were less frequent than with liraglutide (PMID 28050889). In the Harmony Outcomes trial in 9,463 patients with type 2 diabetes and cardiovascular disease, albiglutide reduced major adverse cardiovascular events versus placebo (hazard ratio 0.78) (Lancet, 2018) (PMID 30291013). Concerns were raised about an imbalance in pancreatitis cases and injection site reactions in the approval program (PMID 30063441).
03 · Regulatory status
Albiglutide (Tanzeum) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Albiglutide (Tanzeum) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Albiglutide (Tanzeum) is prescribed for the conditions on its label, and it is not part of our intake. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide Clin Pharmacokinet, 2017. PMID 28050889
- [2]Albiglutide for the management of type 2 diabetes Expert Rev Endocrinol Metab, 2018. PMID 30063441
- [3]Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Lancet, 2018. PMID 30291013
Primary literature
- PubMed: "Albiglutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Albiglutide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Albiglutide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.